

# PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery

NCT07185971

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	NeuroAEye LLC
<b>Enrollment</b>	20 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset
- The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.

### Exclusion (10)

- Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.
- Concurrent use of another visual therapy
- Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)
- Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects
- Insufficient fixation ability

... and 5 more (see full listing online)

## Locations (2 total)

---

Dr. D. M. Fitzgerald & Associates, Cedar Rapids, Iowa, United States  
Neuro-Vision Associates of North Texas, Prospect, Kentucky, United States